|
TYMS expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.66453525910038E-15 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.44089209850063E-16 |
| Normal-vs-Stage2 |
7.2933999994973E-07 |
| Normal-vs-Stage3 |
2.06856753948159E-12 |
| Normal-vs-Stage4 |
6.96180002535129E-09 |
| Stage1-vs-Stage2 |
5.757000E-03 |
| Stage1-vs-Stage3 |
7.785600E-01 |
| Stage1-vs-Stage4 |
3.117200E-01 |
| Stage2-vs-Stage3 |
4.243700E-02 |
| Stage2-vs-Stage4 |
2.131400E-01 |
| Stage3-vs-Stage4 |
4.680800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.44089209850063E-16 |
| Normal-vs-AfricanAmerican |
6.40399999999319E-05 |
| Normal-vs-Asian |
9.90252324584162E-12 |
| Caucasian-vs-AfricanAmerican |
9.741400E-01 |
| Caucasian-vs-Asian |
8.808800E-01 |
| AfricanAmerican-vs-Asian |
9.513800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.61635157983164E-12 |
| Normal-vs-Female |
2.55351295663786E-15 |
| Male-vs-Female |
6.940000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
1.16080478562708E-11 |
| Normal-vs-Age(61-80Yrs) |
6.58329946112701E-10 |
| Normal-vs-Age(81-100Yrs) |
2.170200E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.220400E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.670300E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.582200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.436400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.735200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.168400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.580980E-01 |
| Classical-VS-Follicular |
1.80139999994555E-06 |
| Classical-VS-Other |
7.016200E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
2.1530999999908E-05 |
| Tall-VS-Other |
9.074000E-01 |
| Tall-VS-Normal |
1.77702297321503E-12 |
| Follicular-VS-Other |
4.050400E-02 |
| Follicular-VS-Normal |
3.27060000004931E-06 |
| Other-VS-Normal |
1.872020E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.32844862782622E-13 |
| Normal-vs-N1 |
3.1125000354848E-09 |
| N0-vs-N1 |
2.149200E-01 |
|
|
